News Release

Canada's Cancer Risk Management model is an important new health tool for policymakers

Peer-Reviewed Publication

International Association for the Study of Lung Cancer

If Canada's smoking rates were cut by half to an average national rate of 11% within five years, it would result in 35,900 fewer cases of lung cancer by 2030 and save $656 million in treatment costs, according to analysis using a new web-enabled platform developed for the Canadian Partnership Against Cancer and presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).

"The Cancer Risk Management simulation model developed for the Canadian Partnership Against Cancer simulates the demographic characteristics of the Canadian population and projects cancer occurrences," said the abstract's author, Dr. Bill Evans, M.D., president of the Juravinski Cancer Centre at Hamilton Health Sciences in Hamilton, Ontario, Canada. "For lung cancer, it can be used to explore the impact of smoking cessation on such things as downstream treatment costs, life-years gained and the impacts on tax revenue. It can also project the impact of introducing a population-based screening program or increasing the uptake of adjuvant chemotherapy for surgically resected lung cancer. The cost impacts of new systemic treatments, such as molecular targeted therapies, can be estimated for specific populations, such as stage IV non-small cell lung cancer, with the budget impact for individual provinces. These simulations can help to inform decision-makers as to the relative costs and benefits of proposed new cancer control strategies."

The Cancer Risk Management (CRM) model uses dynamic, longitudinal microsimulation techniques to simulate and project realistic, representative Canadian populations, offering the potential to study changes in screening, prevention, and treatment.

The impact of decreasing smoking rates is provided as an example. For this simulation, smoking rates were decreased over a 5-year time frame from a 22% national average in 2010 to 11%. Over 20 years, this would save 587,000 person-years of life, or an average of 0.09 years per smoker. By 2030, the lung cancer incidence rate would drop from 87 to 72 per 100,000 people, resulting in cumulative savings in direct lung cancer treatment costs of $656 million and a decrease in tax revenue from cigarettes of $81.1 billion. Compared with the 5-year smoking cessation timeframe, achieving a 50% reduction in smoking rates in 3 or 10 years would add 59,800 life-years or reduce them by 117,900, respectively.

Lung, colorectal and cervical cancer modules have been built that incorporate Canadian demographic characteristics (births, mortality, immigration, emigration), educational status, risk factors (e.g. smoking, radon exposure for lung cancer) and economic factors (earnings, taxes, government transfers). CRM uses the latest data on the incidence, disease management and cancer case fatality in Canada, the impact of cancer treatments on population health and the cost to the health care system. Data sources include large national surveys, cancer registries and census data, as well as medical literature and expert opinion.

###

Dr. Bill Evans will discuss the research with journalists during a WCLC press conference at 10 a.m. CET on Wednesday, July 6. For individual interview requests, please call Renée McGaw at +31 20 549 3413 between July 3-7 in the press office at Amsterdam RAI, Amsterdam, the Netherlands. You may also email her at renee.mcgaw@ucdenver.edu

About the IASLC:

The International Association for the Study of Lung Cancer (IASLC), based in Denver, Colorado, U.S.A., is the only global organization dedicated to the study of lung cancer. Founded in 1972, the association's membership includes more than 3,000 lung cancer specialists in 80 countries.

IASLC members promote the study of etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and thoracic malignancies. IASLC disseminates information about lung cancer to scientists, members of the medical community and the public, and uses all available means to eliminate lung cancer as a health threat for the individual patients and throughout the world. Membership is open to any physician, health professional or scientist interested in lung cancer.

IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer. To learn more about IASLC please visit http://iaslc.org/


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.